TScan Therapeutics, Inc.
TCRXNASDAQHealthcare● Active
$0.99
+$0.01(+1.22%)
Market Cap$60701676
P/E Ratio—
52W High$2.57
52W Low$0.882
TScan Therapeutics, Inc. (TCRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TCRX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.22
Est. -$0.22 · +0.0%
Revenue
$0.00B
Est. $0.00B · -60.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss Revenue🔥 5-Quarter EPS Beat Streak
TCRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.27 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 6, 2026 | -$0.22 | -$0.22 | +0.0% | $0.00B | $0.00B | -60.7% |
| ▲ Q1 FY2026 | Mar 4, 2026 | -$0.27 | -$0.18 | +33.3% | $0.00B | $0.00B | +5.4% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.35 | -$0.28 | +20.0% | $0.00B | $0.00B | +29.4% |
| — Q3 FY2025 | Aug 12, 2025 | -$0.28 | -$0.28 | +0.0% | $0.00B | $0.00B | +65.4% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.28 | -$0.26 | +7.1% | $0.00B | $0.00B | +100.1% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -$0.27 | -$0.29 | -7.4% | $0.00B | $0.00B | -56.2% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.28 | -$0.25 | +10.7% | $0.00B | $0.00B | -10.5% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
-$0.22
EPS Est.
-$0.22
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2026
Mar 4, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.27
EPS Surpr.
+33.3%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.35
EPS Surpr.
+20.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025
EPS Actual
-$0.28
EPS Est.
-$0.28
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.28
EPS Surpr.
+7.1%
Revenue
$0.00B
Q1 FY2025
Mar 5, 2025Miss
EPS Actual
-$0.29
EPS Est.
-$0.27
EPS Surpr.
-7.4%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.25
EPS Est.
-$0.28
EPS Surpr.
+10.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.25 | $-0.23 | $-0.21 | 2 |
| Q3 FY2027 | $-0.25 | $-0.23 | $-0.21 | 1 |
| Q2 FY2027 | $-0.24 | $-0.22 | $-0.20 | 1 |
| Q1 FY2027 | $-0.24 | $-0.22 | $-0.20 | 2 |
| Q4 FY2026 | $-0.27 | $-0.25 | $-0.23 | 2 |
| Q3 FY2026 | $-0.45 | $-0.28 | $-0.20 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +0.0% | $1.21 | $1.25 | +3.31% |
| ▲ Q1 FY2026 | Mar 4, 2026 | +33.3% | $1.03 | $1.08 | +4.85% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +20.0% | $1.22 | $1.19 | -2.46% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +0.0% | $1.61 | $1.67 | +3.73% |
| ▲ Q2 FY2025 | May 6, 2025 | +7.1% | $1.50 | $1.36 | -9.33% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -7.4% | $2.02 | $1.92 | -4.95% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +10.7% | $5.70 | $5.42 | -4.91% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +6.7% | $5.92 | $6.00 | +1.35% |
Q2 FY2026+3.31%
Report Date
May 6, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.21
Price After
$1.25
Q1 FY2026+4.85%
Report Date
Mar 4, 2026
EPS Beat/Miss
+33.3%
Price Before
$1.03
Price After
$1.08
Q4 FY2025-2.46%
Report Date
Nov 12, 2025
EPS Beat/Miss
+20.0%
Price Before
$1.22
Price After
$1.19
Q3 FY2025+3.73%
Report Date
Aug 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.61
Price After
$1.67
Q2 FY2025-9.33%
Report Date
May 6, 2025
EPS Beat/Miss
+7.1%
Price Before
$1.50
Price After
$1.36
Q1 FY2025-4.95%
Report Date
Mar 5, 2025
EPS Beat/Miss
-7.4%
Price Before
$2.02
Price After
$1.92
Q4 FY2024-4.91%
Report Date
Nov 12, 2024
EPS Beat/Miss
+10.7%
Price Before
$5.70
Price After
$5.42
Q3 FY2024+1.35%
Report Date
Aug 12, 2024
EPS Beat/Miss
+6.7%
Price Before
$5.92
Price After
$6.00
Avg Beat Reaction-0.49%
Avg Miss Reaction-4.95%
Beat Rate7 / 8 quarters
Largest Move-9.33% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TCRX ends December
TScan Therapeutics, Inc. (TCRX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.22 (in line with the analyst consensus of $-0.22). TCRX has beaten EPS estimates for 5 consecutive quarters. The next TCRX earnings date is expected around September 1, 2026.
Each quarter, investors track TCRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TCRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TCRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TCRX earnings · 4 questionsTScan Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. TCRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TCRX historically reports after market close (AMC).
TCRX earnings datewhen is TCRX earningsTCRX next earnings datewhen does TCRX report earningsTCRX earnings calendar
▸ Source: FMP · TScan Therapeutics, Inc. SEC filings · US GAAP · TScan Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026